Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

摘要

Background Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of administration in a dose-dense regimen have not been defined yet. Methods From July 2005 to November 2008, 1001 patients (990 eligible) were randomized to receive, every 2?weeks, 3?cycles of epirubicin 110?mg/m2 followed by 3?cycles of paclitaxel 200?mg/m2 followed by 3?cycles of intensified CMF (Arm A; 333 patients), or 3?cycles of epirubicin followed by 3?cycles of CMF, as in Arm A, followed 3?weeks later by 9 weekly cycles of docetaxel 35?mg/m2 (Arm B; 331), or 9 weekly cycles of paclitaxel 80?mg/m2 (Arm C; 326). Trastuzumab was administered for one year to HER2-positive patients post-radiation. Results At a median follow-up of 60.5?months, the 3-year disease-free survival (DFS) rate was 86%, 90% and 88%, for Arms A, B and C, respectively, while the 3-year overall survival (OS) rate was 96% in all arms. No differences were found in DFS or OS between the combined B and C Arms versus Arm A (DFS: HR?=?0.81, 95% CI: 0.59-1.11, P =?0.20; OS: HR?=?0.84, 95% CI: 0.55-1.30, P =?0.43). Among the 255 patients who received trastuzumab, 189 patients (74%) completed 1?year of treatment uneventfully. In all arms, the most frequently reported severe adverse events were neutropenia (30% vs. 27% vs. 26%) and leucopenia (12% vs. 13% vs. 12%), while febrile neutropenia occurred in fifty-one patients (6% vs. 4% vs. 5%). Patients in Arm A experienced more often severe pain ( P =?0.002), neurological complications ( P =?0.004) and allergic reactions ( P =?0.004), while patients in Arm B suffered more often from severe skin reactions ( P =?0.020). Conclusions No significant differences in survival between the regimens were found in the present phase III trial. Taxane scheduling influenced the type of severe toxicities. HER2-positive patients demonstrated comparable 3-year DFS and OS rates with those reported in other similar studies. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12610000151?033 .